Interestingly, higher expression of three biomarkers has robust connections with poorer overall survival, relapse-free survival, post-progression survival, and disease-specific survival, indicating that YWHAB, PPAT, and NOL10 are reliable biomarkers to predict prognosis in patients with HCC. The gene discussed is PPAT; the disease is hepatocellular carcinoma.